Zealand Pharma Halts Obesity Drug Dapiglutide Development Amid Crowded GLP-1 Market
核心洞察
Zealand Pharma has paused development of dapiglutide, a GLP-1/GLP-2 dual agonist obesity drug candidate, to focus resources on more differentiated programs in the increasingly competitive weight-loss market.
The decision reflects strategic portfolio management as the company prioritizes survodutide and petrelintide, two obesity assets with partnership backing from Boehringer Ingelheim and Roche respectively.
Dapiglutide showed 11.6% weight loss after 28 weeks in Phase Ib trials, but demonstrating its anti-inflammatory effects would require long and complex studies in the crowded GLP-1 space.
Denmark's Zealand Pharma announced Thursday it has paused development of dapiglutide, an early-stage obesity drug candidate, as the company shifts focus to more promising programs in the increasingly competitive weight-loss market. The decision comes as the booming obesity therapeutics sector, estimated to reach $150 billion annually by the end of the decade, becomes dominated by GLP-1-based treatments.
Strategic Portfolio Realignment
Zealand's decision reflects what the company calls "active portfolio management," prioritizing capital allocation toward programs with the greatest potential for clinical differentiation. The Danish biotech will now focus full resources on two more mature obesity assets: survodutide, a GLP-1/glucagon receptor dual-agonist developed with Boehringer Ingelheim, and petrelintide, an amylin analog being developed in partnership with Roche.
"Zealand is pausing development in recognition of the increasingly crowded GLP-1 space, with demonstration of dapiglutide's potential anti-inflammatory effects requiring long and complex trials," Jefferies analyst Lucy Codrington noted.
Dapiglutide's Clinical Profile
Dapiglutide, a GLP-1/GLP-2 receptor dual agonist, was designed not only for weight loss but also to reduce low-grade inflammation associated with obesity through its GLP-2 pathway activation. Unlike Zealand's partnered assets, dapiglutide was wholly owned by the company.
In the investigator-led DREAM study, a 6-mg dose of dapiglutide achieved a 4.3% reduction in body weight from baseline at 12 weeks, compared to 2.2% with placebo. While this effect did not reach statistical significance, Zealand's Chief Medical Officer David Kendall said the company was "encouraged" by these results.
More promising Phase Ib data released in June showed dapiglutide could lower body weight by 11.6% after 28 weeks. However, William Blair analysts noted the study's "atypical patient characteristics," with more than 90% of participants being male with relatively low baseline weight. The analysts suggested that "given that females tend to experience a greater degree of weight loss, the reported weight loss may provide an underrepresentation of the degree of weight loss that could be observed in a more representative population."
Pipeline Priorities and Timeline
Zealand expects two Phase III topline readouts for survodutide in the first half of 2026, while petrelintide is approaching Phase II data drops in both halves of 2026. The petrelintide program is set to enter late-stage development in the latter part of next year.
Jefferies analysts expect Zealand's petrelintide to deliver 15% to 20% weight loss longer term, though they noted it is "difficult to push a best-in-class narrative until we have more comparable data." The amylin-targeting candidate has shown fewer and less severe gastrointestinal side effects in early trials compared to existing GLP-1 treatments.
Market Context and Financial Outlook
The weight-loss drug market is currently dominated by treatments that mimic the gut hormone GLP-1, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy. A similar amylin candidate from Eli Lilly, eloralintide, recently helped patients lose up to 20.1% of their weight in a mid-stage study and is set to enter late-stage trials next month.
Zealand reported that it expects 2025 operating expenses to range between DKK 2.0 billion and DKK 2.3 billion ($671.57 million), narrowing its earlier forecast of DKK 2.0 billion to DKK 2.5 billion. Denmark-listed shares of Zealand rose more than 5% following the announcement.